Opaleye Management Inc.: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1595855) · Explore on the interactive board
Opaleye Management Inc. disclosed 58 US equity positions worth $1.1bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is LQDA at 17.7% of the reported book, followed by ETON, HROW. The top ten holdings are 64.8% of the book, and the portfolio behaves like about 15 equal-weight positions. Versus the prior filing it opened 13 new positions, added to 14, reduced 12 and exited 9.
What does Opaleye Management Inc. own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 13 new, 14 added, 12 reduced, 9 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | LQDA LIQUIDIA CORPORATION | Healthcare | 17.7% | $195.1m | 2,447,500 | -4% | reduced |
| 2 | ETON ETON PHARMACEUTICALS INC | 9.4% | $103.5m | 2,860,000 | 0% | held | |
| 3 | HROW HARROW INC | Healthcare | 9.2% | $101.9m | 2,400,000 | -15% | reduced |
| 4 | IRON DISC MEDICINE INC | Healthcare | 5.7% | $62.5m | 855,000 | 103% | added |
| 5 | URGN UROGEN PHARMA LTD | Healthcare | 4.8% | $53.0m | 1,439,996 | 1% | added |
| 6 | APGE APOGEE THERAPEUTICS INC | Healthcare | 4.7% | $51.8m | 390,000 | 0% | held |
| 7 | MGTX MEIRAGTX HLDGS PLC | Healthcare | 4.3% | $48.0m | 3,550,000 | 67% | added |
| 8 | SOL-GEL TECHNOLOGIES LTD | 3.4% | $37.1m | 500,000 | 0% | held | |
| 9 | RZLT REZOLUTE INC | 3.0% | $32.8m | 6,300,000 | 0% | held | |
| 10 | TGTX TG THERAPEUTICS INC | Healthcare | 2.7% | $29.4m | 535,000 | 0% | held |
| 11 | IMMX IMMIX BIOPHARMA INC | 2.2% | $24.2m | 2,345,000 | – | new | |
| 12 | CBIO CRESCENT BIOPHARMA INC. | 2.2% | $23.7m | 1,319,351 | 1% | added | |
| 13 | STOK STOKE THERAPEUTICS INC | Healthcare | 2.1% | $22.9m | 700,000 | 0% | held |
| 14 | ALPHA COGNITION INC | 1.9% | $20.9m | 2,895,467 | 13% | added | |
| 15 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 1.8% | $20.3m | 500,000 | 0% | held |
| 16 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.7% | $18.7m | 100,000 | 0% | held |
| 17 | GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 1.6% | $18.0m | 745,000 | – | new |
| 18 | ALMS ALUMIS INC | Healthcare | 1.4% | $15.5m | 550,000 | 0% | held |
| 19 | CDXS CODEXIS INC | Healthcare | 1.4% | $15.3m | 6,785,000 | 0% | held |
| 20 | REPL REPLIMUNE GROUP INC | Healthcare | 1.4% | $15.3m | 1,384,993 | – | new |
| 21 | XOMA ROYALTY CORPORATION | 1.3% | $14.4m | 338,374 | 13% | added | |
| 22 | MBX MBX BIOSCIENCES INC | Healthcare | 1.3% | $14.4m | 260,000 | 0% | held |
| 23 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 1.2% | $13.6m | 122,500 | -0% | held |
| 24 | EDIT EDITAS MEDICINE INC | Healthcare | 1.1% | $12.5m | 3,861,930 | 100% | added |
| 25 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 1.1% | $12.3m | 100,000 | 0% | held |
| 26 | CABA CABALETTA BIO INC | Healthcare | 1.1% | $12.0m | 3,863,800 | 180% | added |
| 27 | QTTB Q32 BIO INC | 1.1% | $11.9m | 931,000 | -26% | reduced | |
| 28 | ANNX ANNEXON INC | Healthcare | 0.9% | $9.8m | 1,714,451 | -26% | reduced |
| 29 | VSTM VERASTEM INC | Healthcare | 0.6% | $6.9m | 1,800,000 | – | new |
| 30 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 0.6% | $6.9m | 1,412,656 | 0% | held |
| 31 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 0.6% | $6.5m | 935,000 | 0% | held |
| 32 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 0.5% | $5.9m | 600,000 | 0% | held |
| 33 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.5% | $5.8m | 310,000 | -10% | reduced |
| 34 | BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 0.5% | $5.3m | 700,000 | 1214% | added | |
| 35 | LYEL LYELL IMMUNOPHARMA INC | 0.4% | $4.8m | 344,025 | 335% | added | |
| 36 | IRD OPUS GENETICS INC | 0.4% | $4.6m | 1,125,000 | 0% | held | |
| 37 | FDMT 4D MOLECULAR THERAPEUTICS IN | Healthcare | 0.4% | $4.4m | 334,437 | 198% | added |
| 38 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 0.4% | $4.2m | 250,000 | 2% | added |
| 39 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 0.4% | $4.1m | 1,185,000 | 3% | added |
| 40 | BDSX BIODESIX INC | 0.4% | $4.1m | 180,000 | -24% | reduced | |
| 41 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 0.3% | $3.4m | 1,000,000 | 5% | added |
| 42 | JBIO JADE BIOSCIENCES INC | Healthcare | 0.3% | $3.2m | 145,000 | -66% | reduced |
| 43 | SANUWAVE HEALTH INC | 0.3% | $3.1m | 306,140 | -69% | reduced | |
| 44 | FBIO FORTRESS BIOTECH INC | 0.2% | $2.7m | 890,000 | -15% | reduced | |
| 45 | DERM JOURNEY MED CORP | 0.2% | $2.5m | 350,000 | -64% | reduced | |
| 46 | PHAT PHATHOM PHARMACEUTICALS INC | Healthcare | 0.2% | $2.0m | 185,589 | – | new |
| 47 | INBX INHIBRX BIOSCIENCES INC | Healthcare | 0.2% | $1.9m | 20,291 | – | new |
| 48 | ENTA ENANTA PHARMACEUTICALS INC | Healthcare | 0.2% | $1.8m | 125,000 | 0% | held |
| 49 | HEMAB THERAPEUTICS HLDGS INC | 0.2% | $1.8m | 47,652 | – | new | |
| 50 | TRAX FIRST TRACKS BIOTHERAPEUTICS | 0.1% | $1.3m | 65,000 | – | new |
What did Opaleye Management Inc. sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| CATX PERSPECTIVE THERAPEUTICS INC | 50.7% | $19.5m |
| AH30 ASSERTIO HOLDINGS INC | 13.2% | $5.1m |
| STRO SUTRO BIOPHARMA INC | 12.4% | $4.7m |
| TECX TECTONIC THERAPEUTIC INC | 9.9% | $3.8m |
| RIGL RIGEL PHARMACEUTICALS INC | 4.9% | $1.9m |
| NXTC NEXTCURE INC | 3.9% | $1.5m |
| PERSPECTIVE THERAPEUTICS INC | 2.2% | $834.0k |
| PLX PROTALIX BIOTHERAPEUTICS INC | 1.9% | $737.8k |
| LB PHARMACEUTICALS INC | 0.9% | $357.7k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 72.8% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Opaleye Management Inc.'s portfolio?
Across every quarter Opaleye Management Inc. has filed, its median largest position is 15.4% of the book and its median top-ten weight is 63.1%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 9.0 completed holding spells, the median lasted 1.0 quarters; 58.0 positions are still open and their final length is unknown.